scholarly journals THE DETRIMENTAL INVASIVENESS OF GLIOMA CELLS CONTROLLED BY GADOLINIUM CHELATE-COATED GOLD NANOPARTICLES

Nanoscale ◽  
2021 ◽  
Author(s):  
Maxime Durand ◽  
Elodie Lelièvre ◽  
Alicia Chateau ◽  
Alexandre Berquand ◽  
Gautier Laurent ◽  
...  
Keyword(s):  
Overall Survival ◽  
Gold Nanoparticles ◽  
Glioma Cells ◽  
Invasive Phenotype ◽  
Gadolinium Chelate ◽  
Short Overall Survival

Glioblastoma are characterized by an invasive phenotype, which is thought to be responsible for recurrences and the short overall survival of patients. In last decade, the promising potential of ultrasmall...

Increased invasive phenotype of CSF-1R expression in glioma cells via the ERK1/2 signaling pathway

2018 ◽  
Vol 26 (5-6) ◽  
pp. 136-144
Author(s):  
Libo Sun ◽  
Huaxin Liang ◽  
Weidong Yu ◽  
Xingyi Jin
Keyword(s):  
Signaling Pathway ◽  
Glioma Cells ◽  
Invasive Phenotype

Delivery of miR-320a-3p by gold nanoparticles combined with photothermal therapy for directly targeting Sp1 in lung cancer

2021 ◽  
Author(s):  
Jiefei Peng ◽  
Ranran Wang ◽  
Wanru Sun ◽  
Minhua Huang ◽  
Rong Wang ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Overall Survival ◽  
Gold Nanoparticles ◽  
Mortality Rate ◽  
Photothermal Therapy ◽  
Therapeutic Targets ◽  
Novel Therapeutic

Lung cancer is the second most common tumor and has the highest mortality rate. Both novel therapeutic targets and approaches are needed to improve the overall survival of patients with...

scholarly journals Resistance to DNA Damaging Agents Produced Invasive Phenotype of Rat Glioma Cells—Characterization of a New in Vivo Model

Molecules ◽  
2016 ◽  
Vol 21 (7) ◽  
pp. 843 ◽  
Author(s):  
Sonja Stojković ◽  
Ana Podolski-Renić ◽  
Jelena Dinić ◽  
Željko Pavković ◽  
Jose Ayuso ◽  
...  
Keyword(s):  
Glioma Cells ◽  
In Vivo Model ◽  
Invasive Phenotype ◽  
Rat Glioma ◽  
Dna Damaging Agents

Blastic transformation in Mexican population with chronic myelomonocytic leukemia treated in a tertiary referral center.

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. e18566-e18566
Author(s):  
Alfonso Alfredo Rivera Duarte ◽  
Alejandra Armengol Alonso ◽  
Elena Tuna-Aguilar
Keyword(s):  
Overall Survival ◽  
Acute Leukemia ◽  
Peripheral Blood ◽  
Chronic Myelomonocytic Leukemia ◽  
Tertiary Referral ◽  
Blastic Transformation ◽  
Tertiary Referral Center ◽  
Short Overall Survival ◽  
Blast Count ◽  
Myelomonocytic Leukemia

e18566 Background: Chronic myelomonocytic leukemia (CMML) is the most aggressive of chronic leukemias, with a short overall survival and a high transformation rate to acute leukemia. We investigated factors related to blastic transformation in Mexican population treated in a tertiary referral center Methods: Records of patients diagnosed with CMML between 2000-2015 were reviewed; patients with incomplete data were excluded. IBM SPSS Statics 21.0 software was used to perform statistical analysis. Results: 54 patients were included, with a median age of 71 years and an overall survival of 16 months. The rate of blastic transformation found was 33% (18 patients), with a time to progression of 9 (0-87) months. Comparing patients who didn’t underwent blastic transformation to those who did, those who progress to acute leukemia tend to be younger (58 vs. 71 years, p = 0.001), have a higher peripheral blood blast count (2% vs. 0%, p = 0.003), where more likely to have immature myeloid precursors circulating in peripheral blood (94% vs. 64%, p = 0.02). In multivariate analysis, age continued to be statistically significant (HR 0.97, 95% IC = 0.929-0.987). There where no statistical difference in the two groups regarding hemoglobin levels (8.2g/dL vs. 10.1g/dL) platelets count (115 X 109 vs. 93 X 109), absolute neutrophil count (5.83 X 109 vs. 5.18 X 109), absolute monocyte count (3.09 X 109 vs. 2.680 X 109), and bone marrow blast count (0 vs. 2%). Cytogenetic considered as high risk was not predictor of blastic progression. Intensive chemotherapy was offered to 7(38.9%) patients, with a complete response rate of 0%, the overall survival was 1.4 months (0-9). Conclusions: Contrary to other reported series;Mexican patients with CMML that progresses to overt acute leukemia were considerably younger, with a higher tumor burden and a very short overall survival. In this population, it is important to consider more aggressive treatments at diagnosis, focusing in high dose chemotherapy and hematopoietic stem cell transplantation in a short term ratter than watching and waiting or using agents that do not impact in disease natural history.

scholarly journals Enhancement of invadopodia activity in glioma cells by sublethal doses of irradiation and temozolomide

2018 ◽  
Vol 129 (3) ◽  
pp. 598-610 ◽  
Author(s):  
Leon Mao ◽  
Clarissa A. Whitehead ◽  
Lucia Paradiso ◽  
Andrew H. Kaye ◽  
Andrew P. Morokoff ◽  
...  
Keyword(s):  
Cell Lines ◽  
Glioma Cells ◽  
Standard Of Care ◽  
Current Treatment ◽  
Central Nervous System Tumor ◽  
Glioblastoma Cells ◽  
Current Standard ◽  
Invasive Phenotype ◽  
Treatment Protocols ◽  
Patient Prognosis

OBJECTIVEGlioblastoma is the most common primary central nervous system tumor in adults. These tumors are highly invasive and infiltrative and result in tumor recurrence as well as an extremely poor patient prognosis. The current standard of care involves surgery, radiotherapy, and chemotherapy. However, previous studies have suggested that glioblastoma cells that survive treatment are potentially more invasive. The goal of this study was to investigate whether this increased phenotype in surviving cells is facilitated by actin-rich, membrane-based structures known as invadopodia.METHODSA number of commercially available cell lines and glioblastoma cell lines obtained from patients were initially screened for the protein expression levels of invadopodia regulators. Gelatin-based zymography was also used to establish their secretory protease profile. The effects of radiation and temozolomide treatment on the glioblastoma cells were then investigated with cell viability, Western blotting, gelatin-based zymography, and invadopodia matrix degradation assays.RESULTSThe authors’ results show that the glioma cells used in this study express a number of invadopodia regulators, secrete MMP-2, and form functional matrix-degrading invadopodia. Cells that were treated with radiotherapy and temozolomide were observed to show an increase primarily in the activation of MMP-2. Importantly, this also resulted in a significant enhancement in the invadopodia-facilitated matrix-degrading ability of the cells, along with an increase in the percentage of cells with invadopodia after radiation and temozolomide treatment.CONCLUSIONSThe data from this study suggest that the increased invasive phenotype that has been previously observed in glioma cells posttreatment is mediated by invadopodia. The authors propose that if the formation or activity of these structures can be disrupted, they could potentially serve as a viable target for developing novel adjuvant therapeutic strategies that can be used in conjunction with the current treatment protocols in combatting the invasive phenotype of this deadly disease.

scholarly journals Key Enzymes in Pyrimidine Synthesis, CAD and CPS1, Predict Prognosis in Hepatocellular Carcinoma

Cancers ◽  
2021 ◽  
Vol 13 (4) ◽  
pp. 744
Author(s):  
Dirk Andreas Ridder ◽  
Mario Schindeldecker ◽  
Arndt Weinmann ◽  
Kristina Berndt ◽  
Lana Urbansky ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Overall Survival ◽  
Cox Regression ◽  
Distant Metastases ◽  
Carbamoyl Phosphate Synthetase ◽  
Carbamoyl Phosphate ◽  
Independent Prognostic Marker ◽  
Pyrimidine Synthesis ◽  
Short Overall Survival

Patients with hepatocellular carcinoma (HCC) have a highly variable clinical course. Therefore, there is an urgent need to identify new prognostic markers to determine prognosis and select specific therapies. Recently, it has been demonstrated that dysregulation of the urea cycle (UC) is a common phenomenon in multiple types of cancer. Upon UC dysregulation, nitrogen is diverted toward the multifunctional enzyme carbamoyl-phosphate synthetase 2, aspartate transcarbamoylase, and dihydroorotase (CAD), and increases pyrimidine synthesis. In this study, we investigated the role of CAD and carbamoyl-phosphate synthetase 1 (CPS1), a rate-limiting enzyme of the UC highly expressed in hepatocytes, in HCC. We created a tissue microarray to analyze expression of both enzymes by immunohistochemistry in a large and well-characterized overall cohort of 871 HCCs of 561 patients that underwent surgery. CAD was induced in recurrent HCCs, and high expression predicted shorter overall survival. CPS1 was downregulated in HCC and further reduced in recurrent tumors and distant metastases. Additionally, low CPS1 was associated with short overall survival. A combined score of both enzymes was an independent prognostic marker in a multivariate Cox regression model (HR = 1.37, 95% confidence interval 1.06–1.75, p = 0.014). Inhibition of pyrimidine synthesis may represent a novel therapeutic strategy for HCC.

Pretreatment Levels of Peripheral Neutrophils and Leukocytes As Independent Predictors of Overall Survival in Patients With American Joint Committee on Cancer Stage IV Melanoma: Results of the EORTC 18951 Biochemotherapy Trial

2007 ◽  
Vol 25 (12) ◽  
pp. 1562-1569 ◽  
Author(s):  
Henrik Schmidt ◽  
Stefan Suciu ◽  
Cornelis J.A. Punt ◽  
Martin Gore ◽  
Wim Kruit ◽  
...  
Keyword(s):  
Overall Survival ◽  
Prognostic Factor ◽  
Interleukin 2 ◽  
Stage Iv ◽  
Progression Free Survival ◽  
Independent Prognostic Factor ◽  
Short Overall Survival ◽  
Leukocyte Counts ◽  
Melanoma Patients ◽  
Stage Iv Melanoma

Purpose An elevated count of blood neutrophils and monocytes recently was shown independently to predict short survival in patients with stage IV melanoma undergoing interleukin-2–based immunotherapy. In this study, we aimed to validate this finding in a large cohort of stage IV melanoma patients. Patients and Methods For this retrospective prognostic study, the data from the European Organisation for the Research and Treatment of Cancer 18951 study were used. Patients were randomly assigned between treatment with dacarbazine, cisplatin, and interferon alfa with or without interleukin-2. Counts of neutrophils and leukocytes were analyzed together with other known prognostic factors: serum lactate dehydrogenase, performance status, metastatic site, and sex. Two multivariate prognostic factor analyses were carried out in the model: one with leukocyte counts and one with neutrophil counts. Results A total of 363 patients were randomly assigned and baseline blood neutrophil and leukocyte counts were available from 316 and 350 patients, respectively. A high neutrophil count (> 7.5 × 109/L) was an independent prognostic factor for short overall survival (hazard ratio [HR], 1.5; 95% CI, 1.1 to 2.1; P = 0.02), and a high leukocyte count (> 10 × 109/L) was an independent prognostic factor of both short overall survival (HR, 1.7; 95% CI, 1.3 to 2.4; P = 0.0005) and short progression-free survival (HR, 1.5; 95% CI, 1.1 to 2.1; P = 0.008). Conclusion A high pretreatment count of neutrophils in blood was confirmed as an independent prognostic factor for short overall survival in stage IV melanoma patients undergoing interleukin-2–based immunotherapy. Furthermore, a high count of leukocytes was an independent prognostic factor for short overall survival and progression-free survival. Both parameters should be useful as stratification factors in clinical trials.

scholarly journals Circulating microRNAs Is a Potential Prognostic Biomarker in Primary Central Nervous System Lymphoma

Blood ◽  
2020 ◽  
Vol 136 (Supplement 1) ◽  
pp. 40-41
Author(s):  
Yan Ma ◽  
Dina Suolitiken ◽  
Bobin Chen ◽  
Xiaoping Xu ◽  
Hui Kang ◽  
...  
Keyword(s):  
Overall Survival ◽  
Blood Sample ◽  
Central Nervous System Lymphoma ◽  
Rank Test ◽  
Pcr Assay ◽  
Circulating Micrornas ◽  
Mirna Microarray ◽  
Log Rank Test ◽  
Differentially Expressed Mirnas ◽  
Short Overall Survival

Backgrounds and purposes Primary central nervous system lymphoma (PCNSL) is a rare subtype of non-Hodgkin's lymphoma. The prognosis of PCNSL is poor and heterogeneous. MicroRNA is associated with prognosis of various cancers. Our study is the first time to compare circulating microRNAs of PCNSL patients with different prognosis using miRNA microarray scanning and find novel microRNAs associated with prognosis of PCNSL by further large-scale validation. Materials and methods From a retrospective cohort, we collected the clinical data of patients who were diagnosed as PCNSL in Huashan Hospital between January 2007 and June 2016. We collected clinical data and blood samples from residual blood routine test of PCNSLs. First, we compared circulating microRNAs between patients with different overall survival (OS) using miRNA microarray scanning. Second, PCR assay was used for miRNAs quantification in blood sample from 6 patients that had long overall survival and other 6 patients that had short overall survival. Further miRNA validation was made by PCR assay in blood sample from 94 patients to validate prognostic value of miRNAs in PCNSLs. The Kruskal-Wallis and Mann-Whitney U tests were used for quantitative parameters and the χ2 square test was used for non-quantitative parameters. Univariate analysis was performed using log-rank test, and survival distributions were analyzed by the Kaplan-Meier curve and log-rank test. Multivariate analysis was done by Cox regression model. Results A total of 90 differentially expressed miRNAs were identified, including 24 up-regulated miRNAs and 66 down-regulated miRNAs using miRNA microarray scanning. Then PCR assay was used for 10 differentially expressed miRNAs quantification in blood sample from 6 patients that had long overall survival and 6 patients that had short overall survival. Mir-21, mir-129-5p, mir-144-5, mir-363-5p, mir-409-3p, mir-1246, mir-1299 and mir-1825 showed no differences between 2 groups, while the expression of mir-455-3P and mir-940 between 2 groups are significantly different (P<0.05). Further validation in 94 patients showed median OS in miR-940 overexpression group was 91 months and in miR-940 low-expression group was 28 months (P=0.0005), while median PFS in miR-940 overexpression group was 25 months and in miR-940 low-expression group was 16 months (P =0.0292). Multivariate analysis of COX model showed miR-940 was independent factors for OS and PFS. Conclusion Circulating mir-940 had prognostic value in PCNSL and was an independent prognostic factor for PCNSL. Figure 1 Disclosures No relevant conflicts of interest to declare.

Sign in / Sign up

Export Citation Format

Share Document